Skip to main content
. 2001 Sep 25;98(20):11720–11724. doi: 10.1073/pnas.171325998

Figure 2.

Figure 2

Effects of low- and intermediate-dose DHA administration before ischemia. Reperfused cerebral ischemia cohort (low dose: n = 21; intermediate dose: n = 16; AA: n = 8; vehicle: n = 17). Nonreperfused cerebral ischemia cohort (intermediate dose: n = 21; AA: n = 14; vehicle: n = 14). (A) Dose-dependent improvements were demonstrated in cerebral blood flow at the time of death (24 h) after reperfused cerebral ischemia (*, P < 0.05 for either DHA doses vs. AA or vehicle). There was a significant increase in cerebral blood flow at death in nonreperfused animals treated with intermediate-dose DHA (*, P < 0.05 vs. both AA and vehicle). (B) Dose-dependent improvements were demonstrated in infarct volume after reperfused cerebral ischemia (Left, **, P < 0.01 for both DHA doses vs. AA and vehicle). Improvement was demonstrated in infarct volume after nonreperfused cerebral ischemia (Right, *, P < 0.05 for intermediate DHA dose vs. vehicle). (C) There was a slight decrease in neurological deficit scores after reperfused cerebral ischemia (Left) in the intermediate-dose DHA-treated animals compared with AA- and vehicle-treated animals (P = NS). There was a significant decrease in neurological deficit scores after nonreperfused cerebral ischemia (Right) in the intermediate-dose DHA-treated animals compared with AA-treated animals (P < 0.05). (D) There was a significant decrease in mortality after reperfused cerebral ischemia (Left) in the low- and intermediate-dose DHA-treated animals compared with vehicle-treated animals (P < 0.05). There was a 50% decrease in mortality after nonreperfused cerebral ischemia (Right) in the intermediate-dose DHA-treated animals compared with vehicle-treated animals (P = NS).